Benzinga · Aug 13, 2026
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36 to $38.
KU
NASDAQ · KURA
Kura Oncology, Inc.
Healthcare · Biotechnology
$11.89
Up+$0.18 (+1.54%)
Updated Aug 22, 2026, 3:55 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 911.06M
- P/E ratio
- -4.23
- Dividend yield
- 0.00%
- 52-week range
- $7.54 – $12.90
- Volume
- 2.03M
- Avg. volume
- 1.89M
Price performance
KURA price history
1M range · 0 trading sessions · Daily adjusted prices
KURA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest KURA news
The latest Smart Investors Daily articles mentioning KURA.
Stock researchCompany · Overview
KURA research
Overview
Company profile and research snapshot.
Company profile
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Outperform | — |
| Jul 28, 2026 | Wedbush | Outperform | — |
| Jun 15, 2026 | Citizens | Market Outperform | — |
| Apr 14, 2026 | Lake Street | Buy | — |
| Mar 24, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call August 12, 2026 4:30 PM EDTCompany ParticipantsGreg Mann - Senior Vice President of Investor Relations...
Benzinga · Aug 12, 2026
Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate
Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 2.67 percent decrease over losses of $(0.75) per share from the
Benzinga · Aug 10, 2026
Kura Oncology Announces Publication Of Manuscript In Blood, Journal Of The American Society Of Hematology, Detailing Discovery And Preclinical Development Of Ziftomenib
– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –– Findings demonstrate differentiated menin binding and activity against
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
